Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Heiko Becker

Showing results (31-40 of 98) with videos related to

Pageof 10
Sort By:
Plos One|September 23, 2016
Molecular Genetic Characterization of Individual Cancer Cells Isolated via Single-Cell PrintingJulian Riba, Nathalie Renz, Christoph Niemöller, et al.
Stroke|February 15, 2023
Prevalence and Therapeutic Implications of Clonal Hematopoiesis of Indeterminate Potential in Young Patients With StrokeErnst Mayerhofer, Christoph Strecker, Heiko Becker, et al.
Experimental Hematology|August 2, 2017
The oligodendrocyte lineage transcription factor 2 (OLIG2) is epigenetically regulated in acute myeloid leukemiaArzu Yalcin, Marlon Kovarbasic, Julius Wehrle, et al.
Frontiers in Oncology|December 15, 2025
Comprehensive molecular profiling of urologic tumors presented in a molecular tumor board: insights from a real-world precision oncology cohortMaximilian Glienke, Ruth Himmelsbach, Max Zirngibl, et al.
Blood|March 10, 2018
Epigenetic regulation of NFE2 overexpression in myeloproliferative neoplasmsJan C Peeken, Jonas S Jutzi, Julius Wehrle, et al.
Annals of Hematology|July 5, 2024
FRACTION: protocol of a phase II study of Fedratinib and Nivolumab combination in patients with myelofibrosis and resistance or suboptimal response to JAK-inhibitor treatment of the German MPN study group (GSG-MPN)Susanne Isfort, Nikolas von Bubnoff, Haifa Kathrin Al-Ali, et al.
Blood Cancer Journal|August 22, 2022
The antileukemic activity of decitabine upon PML/RARA-negative AML blasts is supported by all-trans retinoic acid: in vitro and in vivo evidence for cooperationRuth Meier, Gabriele Greve, Dennis Zimmer, et al.
Leukemia Research|September 24, 2020
Prevalence and characteristics of myeloproliferative neoplasms with concomitant monoclonal gammopathyNora Rebeka Javorniczky, Julius Wehrle, Gabriele Ihorst, et al.
Annals of Hematology|June 7, 2020
Monosomal karyotype and chromosome 17p loss or TP53 mutations in decitabine-treated patients with acute myeloid leukemiaHeiko Becker, Dietmar Pfeifer, Gabriele Ihorst, et al.
Leukemia|October 7, 2025
Genetic and epigenetic alterations at secondary resistance after continued decitabine-based treatment of acute myeloid leukemia in the randomized phase II DECIDER trialInga Hund, Maria Elena Hess, Geoffroy Andrieux, et al.
Pageof 10

Showing results (31-40 of 98) with videos related to

Sort By:
Pageof 10
Plos One|September 23, 2016
Molecular Genetic Characterization of Individual Cancer Cells Isolated via Single-Cell PrintingJulian Riba, Nathalie Renz, Christoph Niemöller, et al.
Stroke|February 15, 2023
Prevalence and Therapeutic Implications of Clonal Hematopoiesis of Indeterminate Potential in Young Patients With StrokeErnst Mayerhofer, Christoph Strecker, Heiko Becker, et al.
Experimental Hematology|August 2, 2017
The oligodendrocyte lineage transcription factor 2 (OLIG2) is epigenetically regulated in acute myeloid leukemiaArzu Yalcin, Marlon Kovarbasic, Julius Wehrle, et al.
Frontiers in Oncology|December 15, 2025
Comprehensive molecular profiling of urologic tumors presented in a molecular tumor board: insights from a real-world precision oncology cohortMaximilian Glienke, Ruth Himmelsbach, Max Zirngibl, et al.
Blood|March 10, 2018
Epigenetic regulation of NFE2 overexpression in myeloproliferative neoplasmsJan C Peeken, Jonas S Jutzi, Julius Wehrle, et al.
Annals of Hematology|July 5, 2024
FRACTION: protocol of a phase II study of Fedratinib and Nivolumab combination in patients with myelofibrosis and resistance or suboptimal response to JAK-inhibitor treatment of the German MPN study group (GSG-MPN)Susanne Isfort, Nikolas von Bubnoff, Haifa Kathrin Al-Ali, et al.
Blood Cancer Journal|August 22, 2022
The antileukemic activity of decitabine upon PML/RARA-negative AML blasts is supported by all-trans retinoic acid: in vitro and in vivo evidence for cooperationRuth Meier, Gabriele Greve, Dennis Zimmer, et al.
Leukemia Research|September 24, 2020
Prevalence and characteristics of myeloproliferative neoplasms with concomitant monoclonal gammopathyNora Rebeka Javorniczky, Julius Wehrle, Gabriele Ihorst, et al.
Annals of Hematology|June 7, 2020
Monosomal karyotype and chromosome 17p loss or TP53 mutations in decitabine-treated patients with acute myeloid leukemiaHeiko Becker, Dietmar Pfeifer, Gabriele Ihorst, et al.
Leukemia|October 7, 2025
Genetic and epigenetic alterations at secondary resistance after continued decitabine-based treatment of acute myeloid leukemia in the randomized phase II DECIDER trialInga Hund, Maria Elena Hess, Geoffroy Andrieux, et al.
Pageof 10